輕鋼架天花板

PPAR agonists all the same?Rosiglitazone belongs to a class of drugs known as peroxisome proliferator-activated receptor (PPAR) agonists. Nissen and Wolski point out that it is not the first of this drug class to be associated with cardiovascular events, as the investigational agent muraglitazar was dropped from late-stage development because of adverse cardiovascular events, and development of many other PPAR agonists has also been stopped after early evidence of toxicity.To heartwire, Nissen commented: "These drugs are very complex, and every one is different in that they all turn on or off different genes, so you can’t really talk about a class effect. They all have to be evaluated separately." He noted that the other major drug in this class--pioglitazone--has shown a reassuring effect on cardiovascular outcomes in a large-scale trial (PROACTIVE). "The PROACTIVE data went in the right direction, so I would say pioglitazone was probably safe," he said.   .msgcontent .wsharing ul li { text-indent: 0; } 分享 Facebook Plurk YAHOO! .